MBRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Moleculin Biotech Inc (MBRX) is not a strong buy for a beginner, long-term investor at this time. The stock shows weak technical indicators, no significant positive catalysts, and poor financial performance. While analysts maintain a Buy rating, the drastic reduction in price targets and lack of recent news or trading trends suggest limited immediate upside potential.
The technical indicators are bearish. The MACD histogram is negative and contracting, RSI is neutral at 24.867, and moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 2.427, with key support at 2.253 and resistance at 2.601.
Analysts maintain a Buy rating, and the Phase2b/3 MIRACLE trial enrollment is progressing as anticipated, with initial results expected in Q1 2026.
Drastic reduction in price targets by analysts following a 1-for-25 reverse stock split. Financial performance is weak, with negative net income and EPS. No significant trading trends or recent news to drive positive sentiment.
In Q3 2025, the company reported zero revenue growth (0.00% YoY), a net income loss of -$25.39 million (up 139.79% YoY), and a significant drop in EPS to -17.02 (-76.13% YoY). Gross margin remains at 0.
Analysts have lowered price targets significantly (from $300 to $31 by Roth Capital and from $4 to $22 by H.C. Wainwright) but maintain a Buy rating. This reflects cautious optimism but highlights significant risks.
